Eurofarma 
Welcome,         Profile    Billing    Logout  
 11 Products   48 Diseases  11 Products   35 Trials   1048 News 
41 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vaxira (racotumomab) / Eurofarma, Recombio
NCT02998983: Racotumomab in Patients With High-risk Neuroblastoma

Completed
2
39
RoW
Racotumomab
Laboratorio Elea Phoenix S.A.
Neuroblastoma
11/22
11/22
Xcopri (cenobamate) / SK Bio
NCT06453213: Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Recruiting
4
90
US
Cenobamate
SK Life Science, Inc.
Focal Onset Seizure
05/27
07/27
2018-002981-37: A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

Ongoing
3
130
Europe, RoW
Cenobamate, YKP3089, Tablet, Film-coated tablet
SK Life Science, Inc., SK Life Science, Inc.
Primary Generalized Tonic-Clonic Seizures, Primary Generalized Tonic-Clonic Seizures, Diseases [C] - Nervous System Diseases [C10]
 
 
ONO-2017-01, NCT06579573: ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.

Recruiting
3
15
Japan
Cenobamate
Ono Pharmaceutical Co. Ltd
Epilepsy, Generalized
01/27
01/27
NCT03961568: Cenobamate Open-Label Extension Study for YKP3089C025

Enrolling by invitation
3
145
Europe, US, RoW
Cenobamate, YKP3089
SK Life Science, Inc.
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
08/26
08/26
NCT04557085: Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS

Active, not recruiting
3
540
Japan, RoW
Cenobamate, Placebo
SK Life Science, Inc.
Partial Seizure, Focal Seizure
02/24
03/25
NCT03678753 / 2018-001337-41: Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

Active, not recruiting
3
169
Europe, US, RoW
Cenobamate, YKP3089, Placebo, PBO
SK Life Science, Inc.
Primary Generalized Epilepsy
08/25
08/25
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
NCT06590896: Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Recruiting
2
100
Japan
Cenobamate
Ono Pharmaceutical Co. Ltd
Epilepsies, Partial
01/27
01/27
NCT04791553: Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Completed
1
15
Europe
Cenobamate, YKP3089
SK Life Science, Inc.
Hepatic Impairment
11/22
08/23
NCT05572255: A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally

Completed
1
24
US
Cenobamate, YKP3089C045
SK Life Science, Inc.
Healthy Volunteers
01/23
01/23
CENOBITE, NCT06352723: Cenobamate in the Intensive Care Unit

Not yet recruiting
1
10
US
Cenobamate
Brigham and Women's Hospital
Epilepsy, Neurologic Disorder
12/24
06/25
NCT04903314: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures

Recruiting
1
24
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
10/25
03/26
CENOR, NCT05747001: This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK

Completed
N/A
319
Europe
Aziende Chimiche Riunite Angelini Francesco S.p.A, Hippocrates Research
Focal Onset Seizure, Epilepsy
09/23
09/23
NCT04879433: Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy

Recruiting
N/A
100
US
Mid-Atlantic Epilepsy and Sleep Center, LLC
Focal Epilepsy
06/23
11/23
BLESS, NCT05859854: Cenobamate in Adults With Focal-Onset Seizures

Recruiting
N/A
1200
Europe
Aziende Chimiche Riunite Angelini Francesco S.p.A, Iqvia Pty Ltd
Epilepsy, Focal-Onset Seizure, Neurological Disorder
09/25
09/25
NCT06716801: Real-world Clinical Response to Cenobamate Early Add-on in France, Germany and Spain

Not yet recruiting
N/A
300
NA
Cenobamate
Aziende Chimiche Riunite Angelini Francesco S.p.A, Iqvia Pty Ltd
Focal Epilepsy with and Without Secondary Generalization
03/27
03/27
NCT06922175: REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

Recruiting
N/A
200
Europe
Aziende Chimiche Riunite Angelini Francesco S.p.A, 1Med
Epilepsy With Uncontrolled Focal-onset Seizures
06/25
06/25
Hanlikang (rituximab biosimilar) / Fosun Pharma, Eurofarma, Farma de Colombia, Abbott
2020-000736-21: A Phase 3 study to evaluate the efficacy and safety of HLX01 versus rituximab (Mabthera®) as treatment for patients with low tumour burden follicular lymphoma.

Not yet recruiting
3
212
Europe
Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection, Mabthera®, HLX01, Concentrate for solution for infusion, Mabthera®
Shanghai Henlius Biotech Inc., Shanghai Henlius Biotech, Inc.
Low tumour burden follicular lymphoma, Disease of the lymph tissue (part of the immune system) that affects a type of white blood cell called B-Lymphocytes., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ChiCTR2000034167: A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HLX01 (Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection) Combined with MTX Therapy in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

Recruiting
3
267
 
During the 24-week study, subjects will be given one course of treatment with HLX01, After the Week 24 study visit, all subjects will continue to be given one course of treatment with HLX01 ;During the 24-week study, subjects will be given one course of treatment with placebo. After the Week 24 study visit, all subjects will continue to be given one course of treatment with HLX01
Chinese Academy of Medical Sciences Peking Union Medical College; Shanghai Henlius Biotech, Inc., Shanghai Henlius Biotech, Inc.
Rheumatoid Arthritis
 
 
RIPPLE, NCT04246359: Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Recruiting
2
52
RoW
Rituximab Biosimilar, HLX01, Pegylated Interferon α-2b
Huiqiang Huang
Lymphoma, B-Cell
06/22
01/23
NCT07038382: A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

Recruiting
2
24
RoW
HLX79 10mg/kg/Placebo+HLX01, HLX79 20mg/kg/Placebo + HLX01, HLX79 30mg/kg/placebo+HLX01
Shanghai Henlius Biotech
Membranous Nephropathy, Lupus Nephritis (LN)
01/27
05/30
ChiCTR2200064195: A clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma

Recruiting
1
100
 
R-BAP chemotherapy regimen and zanubrutinib ;R-BAP chemotherapy regimen and Ibrutinib
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-raised
mantle cell lymphoma
 
 
NCT05506410: A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

Recruiting
N/A
100
RoW
Rituximab, Bendamustine, Cytarabine, Prednisone, BTK inhibitors
Zhengzhou University
Newly Diagnosed Mantle Cell Lymphoma
06/24
12/26
NCT04491721: Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

Enrolling by invitation
N/A
407
RoW
Chinese Academy of Medical Sciences
Diffuse Large B Cell Lymphoma
06/27
07/27
Hercessi (trastuzumab-strf) / Fosun Pharma, Intas, Eurofarma
ChiCTR2100043780: Real world study of trastuzumab (Zercepac) in the treatment of HER2 positive advanced gastric carcer

Recruiting
4
500
 
Zercepac
Jiangsu Province Cancer Hospital; School of Public Health, Peking University, Henlius
advanced gastric carcer
 
 
ChiCTR2100043781: Real world study of trastuzumab(Zercepac) in the treatment of HER2 positive breast cancer

Recruiting
4
9500
 
Zercepac
Jiangsu Province Cancer Hospital; School of Public Health, Peking University, Henlius
Breast cancer
 
 
ChiCTR2100046223: Real world study of trastuzumab(Zercepac) in the treatment of HER2 positive breast cancer

Recruiting
4
500
 
trastuzumab(Zercepac)
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Self-raised
breast cancer
 
 
neo-ECOH study, ChiCTR2100041951: Efficacy and cardiac safety in the neoadjuvant treatment of stage II-III HER2- positive breast cancer with Docetaxel, Carboplatin, Pertuzumab and HLX02: a single-arm study

Recruiting
4
200
 
TCbHP
Guangdong Provincial Hospital of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Horizontal project funding
Breast Cancer
 
 
ChiCTR2200059543: Real world study of trastuzumab (Zercepac)

Not yet recruiting
4
2000
 
Zercepac
Jiangsu Province Cancer Hospital; Jiangsu Province Cancer Hospital, Shanghai Henlius Biotechnology Co., LTD.
breast cancer
 
 
ChiCTR2300076669: Efficacy and safety of AI combined with pyrotinib and trastuzumab (HLX02) compared with AI combined with trastuzumab (HLX02) in patients with metastatic HR-positive/HER2-positive breast cancer: A multi-center trial

Recruiting
4
146
 
Pyrotinib + Trastuzumab (HLX02) + AI; Trastuzumab (HLX02) + AI
Hunan Cancer Hospital; Hunan Cancer Hospital, None
Breast cancer
 
 
ChiCTR-IIR-16007986: Recruitment time 2016.02.29-2016.03.14 An evaluation of the safety and tolerability of different doses of (open study section) HLX02 in Chinese healthy male subjects compared HLX02 and Herceptin (in USA and Germany) the pharmacokinetics, safety phase I clinical study, tolerability and immunogenicity: randomized, double-blind,

Recruiting
1
1776
 
HLV02
First Hospital of Jilin University; First Hospital of Jilin University, Shanghai-Hong Han Lin Biotechnology Co., Ltd.
Metastatic Breast Cancer
 
 
Hanbeitai (bevacizumab biosimilar) / Fosun Pharma, Eurofarma
NCT03511963: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

Completed
3
677
RoW
HLX04 100 mg in 4 ml Injection, Avastin 100 mg in 4 ml Injection
Shanghai Henlius Biotech
Metastatic Colorectal Cancer (mCRC)
04/20
04/23
HLX10-002-NSCLC301, NCT03952403: A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
643
RoW
HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin, Pemetrexed
Shanghai Henlius Biotech
Carcinoma, Non-Small-Cell Lung
10/23
03/24
ASTRUM-015, NCT04547166: A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Recruiting
2/3
568
Japan, RoW
HLX10, serplulimab, HLX04、, Bevacizumab
Shanghai Henlius Biotech
Metastatic Colorectal Cancer
09/25
12/26
NCT03973112: A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Active, not recruiting
2
123
RoW
HLX10 3mg/kg, HLX04 5mg/kg, HLX04 10mg/kg
Shanghai Henlius Biotech
Hepatocellular Carcinoma
06/22
12/22
NCT05290220: HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

Not yet recruiting
2
60
NA
HLX07, HLX10, HLX04, lenvatinib
Shanghai Henlius Biotech
Advanced Hepatocellular Carcinoma
12/23
12/24
NCT04947826: Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis

Not yet recruiting
2
100
NA
HAIC (Hepatic arterial infusion chemotherapy), HLX10 (PD-1 antibody), HLX04 (VEGF antibody), Placebo
Shanghai Zhongshan Hospital, Shanghai Henlius Biotech
Hepatocellular Carcinoma With Major Portal Vein Thrombosis
07/24
07/24
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Recruiting
2
117
RoW
HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo
Shanghai Henlius Biotech
Carcinoma, Hepatocellular
02/27
02/27
ChiCTR-IIR-17010718: Randomized, Double blind, Intravenous, Single dose, Parallel, 4 arm Comparative Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus US sourced Avastin, EU sourced Avastin, and CN sourced Avastin in Healthy Male Subjects

Not yet recruiting
1
208
 
HLX04 supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes. ;US Avastin supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes. ;EU Avastin supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes. ;CN Avastin supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
None; Shanghai Henlius Biotech Inc., Shanghai Henlius Biotech Inc.
Healthy Volunteers
 
 
rizatriptan/naproxen / Eurofarma
NCT04384367: Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine

Completed
3
2068
RoW
Rizatriptan 10 mg + Naproxen 550mg, Medicamento, Maxalt 10Mg Tablet, Flanax 550mg, Placebo oral tablet
Eurofarma Laboratorios S.A.
Migraine
10/24
11/24
Nolazol (mazindol CR) / NLS Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vaxira (racotumomab) / Eurofarma, Recombio
NCT02998983: Racotumomab in Patients With High-risk Neuroblastoma

Completed
2
39
RoW
Racotumomab
Laboratorio Elea Phoenix S.A.
Neuroblastoma
11/22
11/22
Xcopri (cenobamate) / SK Bio
NCT06453213: Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Recruiting
4
90
US
Cenobamate
SK Life Science, Inc.
Focal Onset Seizure
05/27
07/27
2018-002981-37: A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

Ongoing
3
130
Europe, RoW
Cenobamate, YKP3089, Tablet, Film-coated tablet
SK Life Science, Inc., SK Life Science, Inc.
Primary Generalized Tonic-Clonic Seizures, Primary Generalized Tonic-Clonic Seizures, Diseases [C] - Nervous System Diseases [C10]
 
 
ONO-2017-01, NCT06579573: ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.

Recruiting
3
15
Japan
Cenobamate
Ono Pharmaceutical Co. Ltd
Epilepsy, Generalized
01/27
01/27
NCT03961568: Cenobamate Open-Label Extension Study for YKP3089C025

Enrolling by invitation
3
145
Europe, US, RoW
Cenobamate, YKP3089
SK Life Science, Inc.
Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
08/26
08/26
NCT04557085: Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS

Active, not recruiting
3
540
Japan, RoW
Cenobamate, Placebo
SK Life Science, Inc.
Partial Seizure, Focal Seizure
02/24
03/25
NCT03678753 / 2018-001337-41: Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

Active, not recruiting
3
169
Europe, US, RoW
Cenobamate, YKP3089, Placebo, PBO
SK Life Science, Inc.
Primary Generalized Epilepsy
08/25
08/25
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
NCT06590896: Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Recruiting
2
100
Japan
Cenobamate
Ono Pharmaceutical Co. Ltd
Epilepsies, Partial
01/27
01/27
NCT04791553: Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Completed
1
15
Europe
Cenobamate, YKP3089
SK Life Science, Inc.
Hepatic Impairment
11/22
08/23
NCT05572255: A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally

Completed
1
24
US
Cenobamate, YKP3089C045
SK Life Science, Inc.
Healthy Volunteers
01/23
01/23
CENOBITE, NCT06352723: Cenobamate in the Intensive Care Unit

Not yet recruiting
1
10
US
Cenobamate
Brigham and Women's Hospital
Epilepsy, Neurologic Disorder
12/24
06/25
NCT04903314: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures

Recruiting
1
24
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
10/25
03/26
CENOR, NCT05747001: This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK

Completed
N/A
319
Europe
Aziende Chimiche Riunite Angelini Francesco S.p.A, Hippocrates Research
Focal Onset Seizure, Epilepsy
09/23
09/23
NCT04879433: Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy

Recruiting
N/A
100
US
Mid-Atlantic Epilepsy and Sleep Center, LLC
Focal Epilepsy
06/23
11/23
BLESS, NCT05859854: Cenobamate in Adults With Focal-Onset Seizures

Recruiting
N/A
1200
Europe
Aziende Chimiche Riunite Angelini Francesco S.p.A, Iqvia Pty Ltd
Epilepsy, Focal-Onset Seizure, Neurological Disorder
09/25
09/25
NCT06716801: Real-world Clinical Response to Cenobamate Early Add-on in France, Germany and Spain

Not yet recruiting
N/A
300
NA
Cenobamate
Aziende Chimiche Riunite Angelini Francesco S.p.A, Iqvia Pty Ltd
Focal Epilepsy with and Without Secondary Generalization
03/27
03/27
NCT06922175: REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

Recruiting
N/A
200
Europe
Aziende Chimiche Riunite Angelini Francesco S.p.A, 1Med
Epilepsy With Uncontrolled Focal-onset Seizures
06/25
06/25
Hanlikang (rituximab biosimilar) / Fosun Pharma, Eurofarma, Farma de Colombia, Abbott
2020-000736-21: A Phase 3 study to evaluate the efficacy and safety of HLX01 versus rituximab (Mabthera®) as treatment for patients with low tumour burden follicular lymphoma.

Not yet recruiting
3
212
Europe
Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection, Mabthera®, HLX01, Concentrate for solution for infusion, Mabthera®
Shanghai Henlius Biotech Inc., Shanghai Henlius Biotech, Inc.
Low tumour burden follicular lymphoma, Disease of the lymph tissue (part of the immune system) that affects a type of white blood cell called B-Lymphocytes., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
ChiCTR2000034167: A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HLX01 (Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection) Combined with MTX Therapy in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

Recruiting
3
267
 
During the 24-week study, subjects will be given one course of treatment with HLX01, After the Week 24 study visit, all subjects will continue to be given one course of treatment with HLX01 ;During the 24-week study, subjects will be given one course of treatment with placebo. After the Week 24 study visit, all subjects will continue to be given one course of treatment with HLX01
Chinese Academy of Medical Sciences Peking Union Medical College; Shanghai Henlius Biotech, Inc., Shanghai Henlius Biotech, Inc.
Rheumatoid Arthritis
 
 
RIPPLE, NCT04246359: Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Recruiting
2
52
RoW
Rituximab Biosimilar, HLX01, Pegylated Interferon α-2b
Huiqiang Huang
Lymphoma, B-Cell
06/22
01/23
NCT07038382: A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

Recruiting
2
24
RoW
HLX79 10mg/kg/Placebo+HLX01, HLX79 20mg/kg/Placebo + HLX01, HLX79 30mg/kg/placebo+HLX01
Shanghai Henlius Biotech
Membranous Nephropathy, Lupus Nephritis (LN)
01/27
05/30
ChiCTR2200064195: A clinical study of Hanlikang and BTK inhibitors in the treatment of newly diagnosed mantle cell lymphoma

Recruiting
1
100
 
R-BAP chemotherapy regimen and zanubrutinib ;R-BAP chemotherapy regimen and Ibrutinib
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-raised
mantle cell lymphoma
 
 
NCT05506410: A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma

Recruiting
N/A
100
RoW
Rituximab, Bendamustine, Cytarabine, Prednisone, BTK inhibitors
Zhengzhou University
Newly Diagnosed Mantle Cell Lymphoma
06/24
12/26
NCT04491721: Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL

Enrolling by invitation
N/A
407
RoW
Chinese Academy of Medical Sciences
Diffuse Large B Cell Lymphoma
06/27
07/27
Hercessi (trastuzumab-strf) / Fosun Pharma, Intas, Eurofarma
ChiCTR2100043780: Real world study of trastuzumab (Zercepac) in the treatment of HER2 positive advanced gastric carcer

Recruiting
4
500
 
Zercepac
Jiangsu Province Cancer Hospital; School of Public Health, Peking University, Henlius
advanced gastric carcer
 
 
ChiCTR2100043781: Real world study of trastuzumab(Zercepac) in the treatment of HER2 positive breast cancer

Recruiting
4
9500
 
Zercepac
Jiangsu Province Cancer Hospital; School of Public Health, Peking University, Henlius
Breast cancer
 
 
ChiCTR2100046223: Real world study of trastuzumab(Zercepac) in the treatment of HER2 positive breast cancer

Recruiting
4
500
 
trastuzumab(Zercepac)
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Self-raised
breast cancer
 
 
neo-ECOH study, ChiCTR2100041951: Efficacy and cardiac safety in the neoadjuvant treatment of stage II-III HER2- positive breast cancer with Docetaxel, Carboplatin, Pertuzumab and HLX02: a single-arm study

Recruiting
4
200
 
TCbHP
Guangdong Provincial Hospital of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine, Horizontal project funding
Breast Cancer
 
 
ChiCTR2200059543: Real world study of trastuzumab (Zercepac)

Not yet recruiting
4
2000
 
Zercepac
Jiangsu Province Cancer Hospital; Jiangsu Province Cancer Hospital, Shanghai Henlius Biotechnology Co., LTD.
breast cancer
 
 
ChiCTR2300076669: Efficacy and safety of AI combined with pyrotinib and trastuzumab (HLX02) compared with AI combined with trastuzumab (HLX02) in patients with metastatic HR-positive/HER2-positive breast cancer: A multi-center trial

Recruiting
4
146
 
Pyrotinib + Trastuzumab (HLX02) + AI; Trastuzumab (HLX02) + AI
Hunan Cancer Hospital; Hunan Cancer Hospital, None
Breast cancer
 
 
ChiCTR-IIR-16007986: Recruitment time 2016.02.29-2016.03.14 An evaluation of the safety and tolerability of different doses of (open study section) HLX02 in Chinese healthy male subjects compared HLX02 and Herceptin (in USA and Germany) the pharmacokinetics, safety phase I clinical study, tolerability and immunogenicity: randomized, double-blind,

Recruiting
1
1776
 
HLV02
First Hospital of Jilin University; First Hospital of Jilin University, Shanghai-Hong Han Lin Biotechnology Co., Ltd.
Metastatic Breast Cancer
 
 
Hanbeitai (bevacizumab biosimilar) / Fosun Pharma, Eurofarma
NCT03511963: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

Completed
3
677
RoW
HLX04 100 mg in 4 ml Injection, Avastin 100 mg in 4 ml Injection
Shanghai Henlius Biotech
Metastatic Colorectal Cancer (mCRC)
04/20
04/23
HLX10-002-NSCLC301, NCT03952403: A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
643
RoW
HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin, Pemetrexed
Shanghai Henlius Biotech
Carcinoma, Non-Small-Cell Lung
10/23
03/24
ASTRUM-015, NCT04547166: A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Recruiting
2/3
568
Japan, RoW
HLX10, serplulimab, HLX04、, Bevacizumab
Shanghai Henlius Biotech
Metastatic Colorectal Cancer
09/25
12/26
NCT03973112: A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Active, not recruiting
2
123
RoW
HLX10 3mg/kg, HLX04 5mg/kg, HLX04 10mg/kg
Shanghai Henlius Biotech
Hepatocellular Carcinoma
06/22
12/22
NCT05290220: HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

Not yet recruiting
2
60
NA
HLX07, HLX10, HLX04, lenvatinib
Shanghai Henlius Biotech
Advanced Hepatocellular Carcinoma
12/23
12/24
NCT04947826: Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis

Not yet recruiting
2
100
NA
HAIC (Hepatic arterial infusion chemotherapy), HLX10 (PD-1 antibody), HLX04 (VEGF antibody), Placebo
Shanghai Zhongshan Hospital, Shanghai Henlius Biotech
Hepatocellular Carcinoma With Major Portal Vein Thrombosis
07/24
07/24
NCT06349980: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Recruiting
2
117
RoW
HLX53 (1000mg), HLX53 (2000mg), HLX10, Serplulimab, HLX04, Bevacizumab, Placebo
Shanghai Henlius Biotech
Carcinoma, Hepatocellular
02/27
02/27
ChiCTR-IIR-17010718: Randomized, Double blind, Intravenous, Single dose, Parallel, 4 arm Comparative Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus US sourced Avastin, EU sourced Avastin, and CN sourced Avastin in Healthy Male Subjects

Not yet recruiting
1
208
 
HLX04 supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes. ;US Avastin supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes. ;EU Avastin supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes. ;CN Avastin supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
None; Shanghai Henlius Biotech Inc., Shanghai Henlius Biotech Inc.
Healthy Volunteers
 
 
rizatriptan/naproxen / Eurofarma
NCT04384367: Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine

Completed
3
2068
RoW
Rizatriptan 10 mg + Naproxen 550mg, Medicamento, Maxalt 10Mg Tablet, Flanax 550mg, Placebo oral tablet
Eurofarma Laboratorios S.A.
Migraine
10/24
11/24
Nolazol (mazindol CR) / NLS Pharma
No trials found

Download Options